The Global Endometriosis Market size is expected to reach $2.2 billion by 2028, rising at a market growth of 11.6% CAGR during the forecast period.
Endometrial-like tissue that arises in unintended places is a typical symptom of endometriosis. The tissue that develops and sheds in the uterus is known as endometrial tissue. The majority of the time, this growth occurs on and around pelvic cavity organs. Similar to the tissue inside the uterus, endometrial tissue undergoes growth, thickening, and attempts at shedding with each menstrual cycle.
The tissue can result in adhesions, tumors, and lesions that set off an inflammatory reaction since it has no way to leave the body. This may result in discomfort and other issues, such as infertility. Over the years, various causes of endometriosis have been proposed. The endometrium is the name for the lining of the uterus. According to one notion, endometrial cells can go from the uterus to the pelvic region. When a patient has a period, they pour backward along the Fallopian tubes and end up there.
Endometriosis patches have a tendency to be "sticky" and can connect organs. Adhesions are the medical word for this. The gut or bladder, for instance, could "stuck" to the uterus. Large endometriosis patches might develop into cysts that bleed every month during menstruation. The cysts are referred to as "chocolate cysts" and might swell up with black blood.
Without a formal diagnosis, many endometriosis patients receive treatment based solely on their symptoms. In some instances, a laparoscopy, a straightforward surgery, is used to provide an authoritative diagnosis. In this operation, a tiny abdominal incision (often less than 1.5cm/0.6 inches) is made, through which a camera is inserted to view the pelvic cavity. Biopsies, or small tissue samples, can be taken.
The COVID-19 outbreak is projected to have a negative effect on the endometriosis market due to the massive restructuring of medical schools and hospitals around the world to expand hospital capacity for COVID-19 patients. During the pandemic, the development and discovery of endometriosis treatments slowed but did not stop. Healthcare providers were only accepting emergency cases and suggested home care more to the less important cases. Moreover, the shutdown of production facilities and the lack of raw materials like gelatin significantly interrupted the supply chain for endometriosis medications.
Establishing referral networks and care pathways with advanced imaging, pharmaceutical, surgical, fertility, and multidisciplinary interventions at tertiary and secondary centers with good connections to primary healthcare facilities. Increasing the availability of tools (such as ultrasound or magnetic resonance imaging) and medications will help health systems be better equipped to detect and treat endometriosis early (e.g., combined oral contraceptives, non-steroidal analgesics, and progestin-based contraceptives). The market growth will be boosted by numerous significant governmental entities conducting programs and other awareness programs to raise awareness. This would increasingly support the market growth during the projection period.
Endometriosis is a condition in which tissue that resembles the uterine lining grows outside of the uterus, resulting in pain and/or infertility. Around 10% (190 million) of women and adolescents of reproductive age suffer from endometriosis worldwide. It is a chronic condition that causes excruciating, life-altering agony during periods, sexual activity, bowel and/or bladder movements, chronic pelvic discomfort, stomach bloating, nausea, exhaustion, and occasionally depression, anxiety, and infertility.
A diagnostic test's usefulness and validity are primarily determined by its sensitivity and specificity for a certain ailment. However, it can occasionally be challenging to comprehend and apply these measures to clinical decision-making. The likelihood that a positive or negative test would properly identify whether a patient has the condition is known as the positive predictive value (PPV) or negative predictive value (NPV). The endometriosis market is predicted to experience slow expansion due to the absence of appropriate and efficient diagnosis devices.
Based on type, the endometriosis market is segmented into superficial peritoneal lesion, endometriomas and others. The superficial peritoneal lesion segment generated the highest revenue share in the endometriosis market in 2021. This is a result of the increase in the incidence of superficial peritoneal lesions and the creation of programs to raise endometriosis awareness. Additionally, a rise in government financing for endometriosis research has accelerated the development of the superficial peritoneal lesion segment.
On the basis of distribution channel, the endometriosis market is categorized into hospital pharmacy, online pharmacy, and retail pharmacy. The hospital pharmacy segment witnessed the largest revenue share in the endometriosis market in 2021. This is due to an expansion in hospital pharmacies and a rise in patients' confidence in hospitals as providers of high-quality care. The hospital pharmacy market is primarily driven by the growing trend of endometriosis therapy as an alternative to surgery. Hospital pharmacists can also help endometriosis patients, and their carers choose the right medications because they are knowledgeable about medications. Such elements all encourage sector expansion.
By treatment, the endometriosis market is bifurcated into oral contraceptives, gonadotropin-releasing hormone (GnRH) medicines and others. The gonadotropin-releasing hormone (GnRH) medicines segment recorded a prominent revenue share in the endometriosis market in 2021. They are available as a tablet, injection, shot, or nasal spray. Orilissa (elagolix), manufactured by AbbVie Inc., was the first drug given FDA approval to alleviate disease-related pain. Patients who are resistant to the first line of treatment should consider GnRH agonists and antagonists as alternatives.
| Report Attribute | Details |
|---|---|
| Market size value in 2021 | USD 1 Billion |
| Market size forecast in 2028 | USD 2.2 Billion |
| Base Year | 2021 |
| Historical Period | 2018 to 2020 |
| Forecast Period | 2022 to 2028 |
| Revenue Growth Rate | CAGR of 11.6% from 2022 to 2028 |
| Number of Pages | 204 |
| Number of Tables | 350 |
| Report coverage | Market Trends, Revenue Estimation and Forecast, Segmentation Analysis, Regional and Country Breakdown, Companies Strategic Developments, Company Profiling |
| Segments covered | Treatment, Type, Distribution Channel, Region |
| Country scope | US, Canada, Mexico, Germany, UK, France, Russia, Spain, Italy, China, Japan, India, South Korea, Singapore, Malaysia, Brazil, Argentina, UAE, Saudi Arabia, South Africa, Nigeria |
| Growth Drivers |
|
| Restraints |
|
Region wise, the endometriosis market is analyzed across North America, Europe, Asia Pacific and LAMEA. The North America region dominated the endometriosis market with maximum revenue share in 2021. This is mostly linked to an increase in endometriosis cases, which necessitate additional treatments such as gonadotropin-releasing hormone (GnRH) medications, an increase in government financing for endometriosis research, and a considerable increase in capital income in developed countries. The sophisticated reimbursement structures that exist and are designed to lower expenditure levels also contribute to the market's expansion.
Free Valuable Insights: Global Endometriosis Market size to reach USD 2.2 Billion by 2028
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Teva Pharmaceuticals Industries Ltd., Sun Pharmaceutical Industries Ltd., Sanofi S.A., AbbVie, Inc., AstraZeneca PLC, Pfizer, Inc., Merck & Co., Inc., GlaxoSmithKline PLC, Abbott Laboratories, and Consilient Health Limited.
By Type
By Treatment
By Distribution Channel
By Geography
The global Endometriosis Market size is expected to reach $2.2 billion by 2028.
Government efforts to raise endometriosis awareness are driving the market in coming years, however, The absence of non-invasive endometriosis diagnostic tests restraints the growth of the market.
Teva Pharmaceuticals Industries Ltd., Sun Pharmaceutical Industries Ltd., Sanofi S.A., AbbVie, Inc., AstraZeneca PLC, Pfizer, Inc., Merck & Co., Inc., GlaxoSmithKline PLC, Abbott Laboratories, and Consilient Health Limited.
The expected CAGR of the Endometriosis Market is 11.6% from 2022 to 2028.
The Oral Contraceptives segment is leading the Global Endometriosis Market by Treatment in 2021 thereby, achieving a market value of $1.2 billion by 2028.
The North America market dominated the Global Endometriosis Market by Region in 2021, and would continue to be a dominant market till 2028; thereby, achieving a market value of $853.5 million by 2028.
Unique Offerings Our team of dedicated experts can provide you with attractive expansion opportunities for your business.
